As part of our mission to elevate awareness, consolidate research and treatment efforts, and optimize patient outcome for SLC6A1, our CEO, Amber Freed, has begun an advocacy campaign, starting with her recent attendance of an event at the National Institutes of Health in Washington D.C.

“The Growing Promise is Gene Therapy Approaches to Rare Diseases”

SLC-NIH1.jpgSLC6A1 Connect CEO Amber Freed with Debbie Drell (director of Membership for NORD, The National Organization for Rare Disorders), Christopher P. Austin, M.D. (director of the NCATS, National Center for Advancing Translational Sciences, at the National Institutes of Health), and Monica Weldon (President/CEO/Founder of Bridge the Gap – SYNGAP Education and Research Foundation).
SLC-NIH3Amber Freed speaking to the panel at the NIH event in August 2018.
SLC-NIH2Amber Freed with Monica Weldon at the NIH event in August 2018.

2018 Global Genes Rare Patient Advocacy Summit

RAREAmber Freed and Michelle Bassi at Global Genes in October 2018.

2018 Rare Diseases and Orphan Products Breakthrough Summit

AES Speaking

2018 American Epilepsy Society Annual Meeting

AES TableSLC6A1 Booth in the American Epilepsy Society exposition hall.
RoundtableFirst SLC6A1 Symposium in November 2018.